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and above achieved therapeutic levels from in vitro stud-
ies Clearance was rapid (mean half-life 7.1 ± 3.8 to 
15.9 ± 3.6 min). the maximum-tolerated dose was not 
reached at the highest dose evaluated (40 mg/m2 twice 
weekly). grade 2 increase in alanine aminotransferase/
serum aspartate aminotransferase in one patient resolved, 
did not recur upon re-treatment, and was not observed in 
other patients. the only drug-related adverse event was 
transient infusion-related dermatologic reactions (10 
patients). no complete or partial tumor responses were 
observed; seven patients had stable disease of 16 weeks.
Conclusions eP-100 was well tolerated in patients with 
advanced, lHrH-receptor-expressing solid tumors. the 
recommended phase 2 dose is 40 mg/m2 twice weekly for 3 
of 4 weeks per cycle.
Keywords lHrH receptor · eP-100 · Cytolytic peptide · 
Cytolytic peptide conjugate · advanced/metastatic solid 
tumors
Introduction
Human cancer may be targeted via expression of luteiniz-
ing-hormone-releasing hormone (lHrH) receptors [1–18]. 
High lHrH receptor expression is found in diverse tumor 
types, including: prostate [7], breast [2, 8, 9, 12], ovarian 
[10, 11], endometrial [1, 8, 11], pancreatic [12], bladder 
[13], colorectal [14], melanoma [15], renal cancers of clear 
cell and chromophilic papillary histology [16] and non-
Hodgkin lymphoma [18]. Malignant cells typically dis-
play lHrH-receptor overexpression relative to their nor-
mal counterparts, except anterior pituitary basophil cells. 
lHrH receptor typically is not expressed by vital organs 
[19]. lHrH conjugates are being developed to deliver 
Abstract 
Purpose to conduct a phase I study determining the 
safety, pharmacokinetics and preliminary efficacy of eP-
100, a novel anticancer drug consisting of natural luteiniz-
ing-hormone-releasing hormone (lHrH) ligand linked to a 
cationic membrane-disrupting peptide.
Methods Patients with advanced, solid tumors, posi-
tive for lHrH receptor by immunohistochemistry (IHC), 
received eP-100 weekly or twice weekly for 3 of 4 weeks 
in a 28 day cycle. a modified Fibonacci 3 + 3 dose-esca-
lation schema was used. Initial cohorts received eP-100 
once weekly (cohorts 1–7, 0.6–7.8 mg/m2, n = 21). later 
cohorts received doses twice weekly (cohorts 7–11, 7.8–
40 mg/m2, n = 16).
Results lHrH-receptor expression was confirmed by 
IHC in 52 of 89 consented patients; 37 patients received 
at least 1 dose. Cohorts receiving doses of 5.2 mg/m2 
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cytotoxic molecules selectively to malignant cells express-
ing lHrH receptors. examples include lHrH conjugates 
with bovine rnase a [20], pokeweed protein [21, 22] and 
Pseudomonas exotoxin [23]. Proteins involved in apoptosis 
(e.g., BIK, BaK, BaX and DFF40) have been conjugated 
to lHrH [24]. Conjugates of lHrH with cytotoxic agents 
such as doxorubicin, paclitaxel, melphalan, cisplatin and 
methotrexate are under active investigation [25, 26].
One disadvantage of this approach is the release of tox-
ins conjugated to lHrH into systemic circulation, possi-
bly leading to toxicity. lytic peptides conjugated to lHrH 
act rapidly, independently of drug resistance and target-cell 
proliferation, do not require release of the toxic domain by 
linker cleavage, and delivery to non-lHrH-receptor-over-
expressing cell membranes is limited, reducing the natural 
antigenicity and hemolytic activity of lytic peptides.
lytic peptides contain an α-helical domain that interacts 
with negatively charged membranes, causing cell death 
through membrane lysis [27–29]. Internalization and mito-
chondrial toxicity may also be involved [30]. Plasma mem-
brane disruption [31] and apoptosis via upregulation of 
death effectors [32] or by mitochondrial membrane perme-
abilization or change of mitochondrial membrane potential 
[28, 33] are proposed mechanisms by which lytic peptides 
cause cell death.
eP-100 is a synthetic 28 amino acid consisting of the 
lHrH natural ligand joined to an 18 amino acid cationic 
α-helical lytic peptide (ClIP-71) without a linker. lHrH 
delivers the lytic peptide to cancer cells via specific binding 
to cell-surface lHrH receptors. although eP-100’s exact 
mechanism of action has not yet been resolved, cancer 
cell membrane surface characteristics are believed to play 
a critical role. Cancer cells are highly negatively charged, 
containing up to sevenfold higher phosphatidyl serine (PS) 
levels in their outer membrane, whereas normal cells have 
a neutral outer membrane and contain PS only in the inner 
plasma membrane [34, 35], resulting in greater sensitivity 
of a cancer cell membrane to a cationic lytic peptide. Upon 
accumulation on the cell membrane via lHrH receptor tar-
geting, it is believed that eP-100 interacts with the nega-
tively charged membrane, causing it to disintegrate, result-
ing in lysis and cell death. this cytotoxic activity has been 
demonstrated in vitro, with cell-death proteases released 
from cells within minutes at low micromolar concentra-
tions of eP-100, but not in the presence of the untargeted 
lytic peptide [36]. Cancer cells exposed to eP-100 showed 
membrane disintegration as early as 5 min, and complete 
cell lysis occurred after incubation with the drug for 1 h.
Pre-clinical studies of eP-100 have demonstrated in vitro 
activity at sub-micromolar levels in various human cancer 
cell lines from solid tumors and hematological malignan-
cies expressing the lHrH receptor, [esperance data on file, 
37]. In vivo activity was demonstrated in mice implanted 
with lHrH-receptor-positive human ovarian cancer cell 
line (OVCar-3), where three weekly doses given as single 
bolus injection as low as 0.2 mg/kg resulted in decreased 
Ca-125 levels and tumor regression. Unconjugated lytic 
peptide was inactive [36], indicating that a high density of 
lHrH receptors is necessary for sufficient delivery of lytic 
peptide to cause cell lysis (necrosis). repeated dose toxi-
cology studies showed that doses as high as 2.0 mg/kg were 
well tolerated in mice and dogs (esperance data on file). 
the studies demonstrated expected pharmacologic effects 
of eP-100, including a reduction in pituitary production of 
luteinizing hormone (lH) and follicle-stimulating hormone 
(FSH) in some animals, which was associated with reduc-
tion in size of reproductive tissues (uterine and epididymal 
weights) in females and males.
the eP-100 profile of safety, pharmacokinetics (PK), 
pharmacodynamics (PD) and antitumor activity provides 
the basis for therapeutic human trials. Here, we report the 
first-in-human study of eP-100 in subjects with advanced 
solid tumors expressing lHrH receptor.
Methods
Study design and dose escalation
an open-label dose-escalation study was conducted at three 
centers after review and approval by each centers’ Institu-
tional review Board. Patients’ written informed consent 
was provided prior to study enrollment. the primary objec-
tives of the study were to determine the maximum-toler-
ated dose (MtD) of eP-100 by intravenous (IV) infusion 
and to describe any dose limiting toxicities (Dlt), which 
would inform the recommended phase 2 dose (rP2D) of 
eP-100 for future phase 2 protocols. Secondary objectives 
included: (a) to profile the PK and PD of eP-100, (b) to 
assess any drug immunogenicity by antidrug antibodies 
(aDa) which may react with endogenous lHrH, (c) to 
monitor biomarkers of pharmacologic activity of eP-100 
and (d) to assess antitumor activity of eP-100 by radio-
graphic assessments.
Cohorts of three patients were enrolled in a 3 + 3 dose-
escalation design. the highest non-severely toxic dose from 
repeat-dose animal studies was 2.0 mg/kg/dose; BSa con-
version to human mg/m2 suggested 40 mg/m2, and transla-
tion by a FDa safety factor for cytotoxic agents [38] gave a 
safe human by starting dose of 6.6 mg/m2 or 0.17 mg/kg for 
a 65-kg patient. a conservative first-in-human starting dose 
of 0.6 mg/m2 was chosen, based on the repeat-dose toxic-
ity studies in dogs (which appeared to be the most sensi-
tive species). the initial dose schedule of one 30 min infu-
sion weekly was predicted from animal PK profiles. Dosing 
frequency and infusion time were increased in subsequent 
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cohorts by two protocol amendments. to increase the 
cumulative dose-exposure to eP-100, infusions were 
increased to twice weekly after conducting safety assess-
ments in the first seven cohorts (n = 21 patients, at dose 
levels 0.6–7.8 mg/m2). twice weekly infusions effectively 
doubled the eP-100 delivered in all patients after cohort 
7. the infusion time for the twice weekly doses also was 
increased from 30 to 60 min beginning with one patient 
in cohort 8 (dose level 11.7 mg/m2), which decreased the 
intensity of infusion reactions (described below).
the absence of grade 2 drug-related toxicities in lower 
dose cohorts allowed 100 % dose acceleration. In the event 
of grade 2 or higher non-Dlt in one or more patients, dose 
was escalated by 50 %. Dose escalation was limited to 
50 % for any grade 1 or 2 drug-related dermatologic reac-
tions unlikely to be allergic reaction or histamine-release 
syndromes and to 25 % for any grade 3 or 4 drug-related 
infusion reaction. With occurrence of the first Dlt, the 
cohort was expanded to three additional patients. If one 
or more of the three additional patients at that dose level 
experienced Dlt (total of two or more patients with Dlt), 
MtD was reached. MtD was defined as the dose level 
below which two out of three to six patients experienced 
a Dlt during the first cycle or during 1 complete cycle 
(28 days).
Dose reduction to that previously demonstrated safe 
(i.e., the previous cohort) was permitted to manage a 
patient’s hematologic or non-hematologic toxicity. eP-100 
administration was to be discontinued in case of grade 3 or 
4 non-hematologic drug-related toxicity or for Dlt, caus-
ing a treatment delay of more than 3 weeks. eP-100 dosing 
continued until disease progression, unacceptable toxicity 
or voluntary withdrawal from the study. Concomitant ther-
apy with lHrH agonists was permitted.
Patient selection
Patients were 18 years or older with histologically con-
firmed, lHrH-receptor-positive solid tumors. lHrH-
receptor expression was confirmed by immunohistochem-
istry (IHC) on archival tumor tissue sent to a reference 
laboratory prior to study enrollment. Since pre-clinical 
studies showed the highest eP-100 activity in breast, ovar-
ian, endometrial and prostate cancers and non-Hodgkin 
lymphoma, only patients with these cancers were selected 
beginning at dose level 5.2 mg/m2, possibly increasing the 
chance of clinical response at plasma concentrations effica-
cious in pre-clinical models.
Patients were eligible if they demonstrated lHrH-
receptor-positive tumors, had a history of disease progres-
sion after standard/approved therapy and/or had no stand-
ard therapy available. the patients may not have been 
treated with radiation or investigational therapies within 
4 weeks prior to Day 1 and should not have received chem-
otherapy within 3–5 half-lives of the chemotherapy agent 
or 4 weeks prior to Day 1. the patients believed to ben-
efit from hormonal manipulation therapies (e.g., estrogen/
progesterone receptor-overexpressing breast cancer not 
previously treated with hormonal therapy or prostate can-
cer not previously treated with anti-androgen therapy) were 
excluded. the patients with conditions predisposing to his-
tamine release (e.g., mastocytosis, asthma and other aller-
gic disorders with increased mast cell numbers) also were 
excluded. See Supplementary Information for full inclu-
sion/exclusion criteria.
assessments
a history and physical examination were conducted pre-
study and before every cycle. a complete blood count, 
serum electrolytes and chemistries were evaluated pre-
study and then weekly. tumor response or progression was 
assessed by imaging studies at baseline and after every 2 
cycles. reCISt version 1.1 criteria were used to assess 
response.
FSH and lH levels as well as testosterone in men and 
estradiol levels in women were obtained on Days 1, 8, 15 
and 22 within 24 h prior to dosing. testosterone and estra-
diol levels were measured on Day 1 only after Cycle 1 and 
at off study assessment. Blood was collected for circulat-
ing tumor cells (CtC) prior to dosing on Day 1 of the first 
cycle. Patients with positive CtC at baseline also had blood 
collected for CtC analysis prior to dosing on Day 1 of each 
subsequent cycle. additional studies included plasma cor-
tisol, adrenocorticotropin (aCtH), thyroxine (t4) and 
thyroid-stimulating hormone (tSH) and blood for tumor 
specific biomarker analysis (at investigator’s discretion), all 
obtained prior to Day 1 dosing with each cycle and at off 
study assessment. Samples for antidrug antibodies (aDa) 
were collected on Day 1 of Cycle 1 and then on Day 1 of 
every odd cycle.
tumor lHrH-receptor expression
Immunoperoxidase staining was performed on slides from 
archival paraffin-embedded tissue. tumor specimens were 
sent from clinical sites to a central pathology laboratory 
(Pathology group of louisiana, Baton rouge, la). testing 
was performed using the gnrH (lHrH)-receptor mouse 
monoclonal antibody (Clone a9e4, Vector laboratories, 
VP-g811, Burlingame, Ca), and nIeW DaB Detection Kit 
(Ventana Medical Systems, Inc., tucson, aZ). Immunoper-
oxidase stains were performed on one of the Ventana Xt, 
Ventana Benchmark or Ventana nexus units and analyzed 
utilizing the Ventana Image analysis System, an adjunc-
tive computer-assisted image analysis system functionally 
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connected to an interactive microscope (axio Imager, Carl 
Zeiss, nY). Quantitative analysis was performed according 
to the program for the Her2/neu receptor, which includes 
morphometric and colorimetric analysis. receptor staining 
intensity was reported as 0, 1 + (1–25 %), 2 + (26–50 %) 
or 3 + (51–75 %), and was confirmed manually by a single 
experienced pathologist.
Safety
all adverse events (ae) were graded and reported accord-
ing to national Cancer Institute Common terminology 
Criteria for adverse events version 3.0 (nCI CtCae 3.0). 
Dlt were recorded during Cycle 1 if patients had any of 
the following: grade 4 neutropenia lasting 5 or more days, 
grade 3/4 neutropenia with fever and/or infection, grade 4 
thrombocytopenia or grade 3 thrombocytopenia with bleed-
ing, grade 3 or 4 allergic reaction, grade 3 or 4 drug-related 
non-hematologic toxicity (not including grade 3 nausea/
vomiting or diarrhea with sub-optimal prophylactic and 
curative treatment) or a dose delay of more than 2 weeks 
due to treatment-related ae or laboratory abnormalities. 
any grade 3 ae not judged to be clinically significant (e.g., 
alopecia or drug-related fever) were not considered Dlt.
Pharmacokinetics and pharmacodynamics
Blood samples (approximately 5 ml) were collected on 
Cycle 1 Day 1 at the following times: pre-dose, 10 and 
20 min after start of eP-100 infusion, prior to comple-
tion of the infusion (−3 min) and 2, 15, 30, 60 (±2), 120 
(±2) and 240 (±5) min after the infusion. Concentrations 
of eP-100 in eDta-anticoagulated plasma were assayed 
by a validated HPlC-Mass Spectrometry method devel-
oped at Covance (Indianapolis, In). eP-100 and the inter-
nal standard were extracted from human plasma by solid-
phase extraction and analyzed using liquid chromatography 
with tandem mass spectrometric detection (MS/MS). the 
lower limit of quantitation for eP-100 in human plasma 
was 0.025 μg/ml, with linearity demonstrable to 5 μg/ml 
(upper limit of quantitation). Plasma PK analysis for eP-
100 was performed using non-compartmental methods with 
Phoenix™ Winnonlin® version 6.1 or higher (Pharsight 
Corp., Mountain View, Ca). Concentration–time profiles 
were constructed from the plasma sample data. estimates of 
the area under the plasma concentration time curve (aUC) 
and slope of the terminal decay phase were used to calcu-
late values of the following pharmacokinetic parameters: 
apparent terminal phase half-life (t1/2), total body clearance 
(Cl), apparent time of maximum concentration (Tmax) and 
apparent volume of distribution (Vz). Means and standard 
deviations are presented where applicable. Phoenix™ Win-
nonlin® was used to identify the terminal linear phase of 
the concentration–time profile. the number of points cho-
sen was determined based on the largest regression coef-
ficient, R2, obtained. a minimum of three data points was 
used for determination of λz, the elimination rate constant, 
determined by the slope of the terminal linear phase. the 
R2 had to be ≥0.8 to be included in the pharmacokinetic 
results. Summary statistics were prepared using Microsoft 
excel 2007, and graphics were prepared with SigmaPlot™ 
version 11.2 (Systat Software Inc., richmond, Ca).
antidrug antibodies
aDa were evaluated using an enzyme linked immunoas-
say validated for the detection of antibodies against eP-
100 (anti-eP-100) (Icon plc, formerly Prevalere life Sci-
ences, llC, Whitesboro, nY). antibodies were produced 
in rabbits against the lytic peptide moiety of eP-100 (aPC 
338983). antibodies against eP-100 in human serum were 
detected by coating 96-well microtiter plates with peptide 
338983. at least two wells from each plate were coated 
with human Igg at 500 ng/ml as controls for the goat anti-
human horseradish peroxidase detector. rabbit anti-eP-100 
polyclonal antibody was used as a positive control. the 
plates were washed, and a mixture of goat antirabbit HrP 
and goat antihuman HrP and tetramethylbenzidine perox-
ide substrate were added, and the color development deter-
mined in a spectrophotometer at 450 and 620 nm wave-
length. the developed color was proportional to the amount 
of anti-eP-100 antibody in the sample. the anti-eP-100 
antibodies in serum were quantified from a calibration 
curve prepared from the positive control and ranged from 
500 to 32,000 ng/ml in 100 % human serum.
Statistical analyses
PK, PD, safety and tumor response data were summarized 
using descriptive statistics. analysis of variance (anOVa) 
was used to compare PK variables, laboratory safety results 
and antitumor activity at different doses and to identify 
trends in peak plasma drug and metabolite concentra-




eighty-nine (89) patients with advanced cancers were con-
sented and had tissue blocks or slides available for lHrH-
receptor screening. lHrH receptors were expressed on 
tumors from 52 patients (58 %). lHrH-receptor-positive 
expression rate was highest for breast (89 %, 17 of 19) and 
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ovarian (65 %, 11 of 17) cancers, all of which were scored 
as 1+. One of two pancreatic cancers and one of four colo-
rectal cancers scored 2+. One non-Hodgkin lymphoma 
and one carcinoid tumor scored 1+ for lHrH receptors. 
thirty-seven patients received at least 1 dose of eP-100 as 
single agent. Demography for these patients is presented in 
table 1. Median treatment duration was 8.7 weeks (range 
2–25 weeks), with 35 patients completing at least 4 weeks. 
See Fig. 1 for the range of treatment duration by dose level 
for the 11 cohorts.
Dose escalation
eleven dose levels were explored: 0.6, 0.9, 1.35, 1.7, 2.6, 
5.2, 7.8, 11.7, 17.5, 26 and 40 mg/m2. to increase drug 
exposure, twice weekly infusions (30 min) were given to 
each cohort after dose level 7.8 mg/m2, and infusion time 
was increased from 30 to 60 min beginning with one 
patient at dose level 11.7 mg/m2. no toxicities ≥grade 3 
were reported. MtD was not reached at the highest dose 
level evaluated. an isolated occurrence of grade 2 increase 
Table 1  Patient characteristics 
and demographics
number of patients N = 37
Female (N = 28) Male (N = 9) all patients
age (years)
 Median (range) 59 (39–80) 64 (47–73) 61 (39–80)
race
 Caucasian/white 24 9 33
 american Indian or alaska native 2 0 2
 native Hawaiian or Pacific Islander 1 0 1
 asian 1 0 1
 Performance status at baseline (Karnofsky) 90 (80–100) 90 (80–100) 90 (80–100)
time since diagnosis of metastatic cancer to consent (months)
 Median (range) 36.5 (1–192) 18 (1–29) 27 (1–192)
time since primary diagnosis to consent (months)
 Median (range) 71.5 (1–251) 25 (13–97) 60 (1–252)
Histology
 Breast 15 15
 Ovarian, fallopian and granulosa 8 8
 endometrial 3 3
 Pancreatic 2 2
 Prostate 1 1
 non-Hodgkin lymphoma 1 1
 Carcinoid 2 2
 Colon 1 3 4
 Cholangiocarcinoma 1 1
Prior treatments
 Platinum 11 5 16
 taxane 18 2 20
 Platinum and taxane 11 0 11
 anthracycline 20 1 21
 antimetabolites 23 10 33
 Immunotherapies 11 3 14
 anti-angiogenic agents 8 3 11
 Hormone therapy 15 3 18
 Investigational therapy 4 3 7
treatment intend
 First line 1 4 5
 adjuvant 12 2 14
 neoadjuvant 7 1 8
 Palliative 18 3 21
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in alanine aminotransferase/serum aspartate aminotrans-
ferase (alt/aSt) in a patient receiving 11.7 mg/m2 led the 
study investigators, in conjunction with the sponsor medi-
cal monitor, to enroll three more patients at the 11.7 mg/
m2 dose to provide assurance of hepatic safety. the patient 
was a 46-year-old female with infiltrating ductal carcinoma 
metastatic to liver and bone at baseline. Her alt and 
aSt increased during 2 weeks of dosing. Serum biliru-
bin remained within normal limits, and the enzyme levels 
returned to baseline 2 weeks after dose interruption. the 
increased alt/aSt did not recur on continued treatment. 
no other patient in that cohort or in subsequent higher 
dose cohorts experienced a clinically significant increase in 
liver enzymes, and this finding did not meet the definition 
of a Dlt. no further Dlts were observed among the three 
additional patients treated at this dose level.
Safety
table 2 lists selected treatment-related ae. Other ae not 
presented in the table included: infusion site hypersen-
sitivity (n = 4 patients, 10.8 %), two patients each with 
decreased appetite, rhinorrhea and hyperhidrosis (5.4 %), 
and one patient each with “pain,” candidal infection, 
hypokalemia, muscle spasm, peripheral neuropathy, tremor, 
epistaxis, pruritus, macular rash and hot flushes (2.7 %). 
there were no grade 3 or 4 ae in any patients. all ae were 
classified as unrelated or unlikely related to eP-100, with 
the exception of infusion-related dermatologic reactions 
(IrDrs).
the most frequent ae, occurring at the time of eP-100 
infusions, were IrDrs. IrDrs is a term chosen to describe 
a spectrum of skin reactions occurring during eP-100 infu-
sion and reported by investigators as “infusion reaction/
hypersensitivity,” “cytokine release syndrome,” or “urti-
caria.” IrDrs were reported in 10 of 37 patients. Symp-
toms included superficial burning and/or pruritus, with or 
Fig. 1  Duration of eP-100 
treatment in weeks by patient at 
each tested eP-100 dose level. 
tumor histologies of patients 
treated for at least 16 weeks (or 
beyond) are indicated
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Table 2  Selected toxicities (all cycles)
AST serum aspartate aminotransferase, ALT alanine aminotransferase, 
AP alkaline phosphatase
(N = 37) grade 1/2
no. of patients (%)
grade 3/4
no. of patients (%)
Constitutional






 aSt/alt 1 (2.7) 0
 aP 1 (2.7) 0
 total bilirubin 0 0
gastrointestinal
 Diarrhea 1 (2.7) 0
 gastroesophageal reflux 1 (2.7) 0
 Vomiting 1 (2.7) 0
Hematological
 Hemoglobin 0 0
 Platelets 0 0
 neutrophils 0 0
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without diffuse erythema or flushing, and with small pap-
ules or atypical hives on the trunk and/or upper extremities. 
Symptoms were variable in extent and severity, with none 
more than grade 2. Hemodynamic instability and hypoxia 
were not observed. reactions began within 15 min of the 
drug infusion and began to dissipate almost immediately 
after cessation of the infusion. typically, all symptoms 
disappeared within 30 min and were not associated with 
major organ dysfunction or clinically significant sequelae. 
Hematology and chemistry profiles were unchanged, with-
out eosinophilia or indications of inflammatory response. 
One patient reported accompanying shortness of breath 
and chest tightness, but had no substernal pain, changes 
on eCg or in hemodynamic parameters. IrDrs appeared 
to be patient specific and variable, occurring both with the 
first and sometimes subsequent infusions. IrDrs did not 
predictably recur in each patient. temporary interruption 
of the infusion allowed the reaction to subside. there was 
no correlation of IrDrs to tumor type, gender or treat-
ment cycle number (first vs subsequent). no IrDrs were 
reported in the four lowest dose cohorts (0.6–1.7 mg/
m2 at dose concentrations of 0.01–0.03 mg/ml). IrDrs 
incidence was lower when eP-100 infusion times were 
increased from 30 to 60 min (beginning with cohort 7), 
which effectively reduced circulating drug concentration by 
50 %. IrDrs incidence then increased again in the higher 
dose cohorts (17.5 mg/m2, 0.26 mg/ml).
Management of IrDrs included cessation of the infu-
sion until symptoms resolved. Investigators reported 
improved symptoms by administering an antihistamine 
(such as diphenhydramine or hydroxyzine), a corticos-
teroid (such as dexamethasone) and/or and H2-antagonist 
(such as famotidine or ranitidine). Once symptoms had 
resolved and the patient appeared clinically stable, infu-
sions were restarted at a slower rate, without recurrence 
of symptoms in the majority of patients. after observing 
repeated IrDrs in one patient at dose level 2.6 mg/m2 in 
Cycle 3, a consistent pre-treatment regimen was recom-
mended for all patients and included an antihistamine (typi-
cally hydroxyzine or diphenhydramine), an H2-antagonist 
such as famotidine or ranitidine and a corticosteroid, such 
as dexamethasone, to be administered prior to all eP-100 
infusions. Despite pre-treatment, IrDrs recurred with 
subsequent cycles in six patients; in two patients IrDrs 
occurred twice, and in two patients several occurrences 
were recorded.
Fourteen Sae were recorded (table 3). all were grade 
1 or 2. all were judged by the investigators as unrelated or 
unlikely related to eP-100. there was one reported death 
within 1 month of withdrawal from the trial; the death was 
attributed to disease progression in a 49-year-old female 
with serous papillary carcinoma metastatic to liver.
Pharmacokinetics
eP-100 plasma concentrations increased rapidly with 
intravenous administration, and duration of Cmax levels 
were extended with lengthening of the infusion time from 
30 to 60 min beginning with cohort 7. Cmax was reached 
within 20–40 min when eP-100 was given over 30 min, 
and within 40–60 min when eP-100 was given over 
60 min in the majority of patients (Fig. 2a, b). eP-100 
concentrations declined in an exponential fashion after 
approximately 40 min in the 30-min infusion cohorts, 
and after approximately 60 min in the 60-min infusion 
cohorts. the goodness-of-fit statistic for estimation of 
λz (R2) was >0.8 for eP-100 for all subjects analyzed; 
hence, λz was considered reliable, and this parameter and 
associated parameters were reported for all subjects. the 
increase in Cmax with dose appeared to be slightly greater 
Table 3  treatment-emergent serious adverse events (Sae)
Qw, weekly; biw, twice weekly
Sae no. of patients (%) Dosing, mg/m2 (no. of patients) relationship to eP-100 Outcome
gastrointestinal obstruction 2 (5.4) 0.6, 0.9 qw Unrelated resolved with sequelae
gastrointestinal hemorrhage 1 (2.7) 1.35 qw Unlikely related resolved
Peripheral edema 1 (2.7) 1.35 qw Unrelated resolved with sequelae
Disease progression 1 (2.7) 1.35 qw Unrelated Death
Pain 1 (2.7) 1.7 qw Unrelated Ongoing
Hydronephrosis 1 (2.7) 11.7 biw Unrelated resolved
Chills 1 (2.7) 11.7 biw Unrelated resolved
Pleural effusion 2 (5.4) 11.7, 26 biw Unrelated resolved
Febrile neutropenia 1 (2.7) 17.5 biw Unrelated resolved
ascites 1 (2.7) 26 biw Unlikely related resolved with sequelae
Fatigue 1 (2.7) 26 biw Unrelated resolved
Facial paresis 1 (2.7) 40 biw Unrelated Ongoing
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than dose proportional; however the data were highly 
variable (Fig. 3). aUC0–t and aUC0–∞ also appeared 
to increase in a nonlinear manner relative to dose. the 
percent of aUC extrapolated was less than 20 % for all 
dose groups, suggesting that the sample collection period 
was sufficient to characterize the concentration versus 
time curves. the volume of distribution, Vz, appeared to 
decrease with an increase in dose. Vz ranged from 4,346.6 
to 1,564.4 ml in going from a dose of 0.6–5.2 mg/m2, 
respectively. Following doses of 7.8 to 17 mg/m2, Vz 
remained relatively constant and ranged from ~2,400 to 
2,666 ml (~60 ml/kg).
Clearance was variable but generally decreased with an 
increase in dose and ranged from 299.0 to 142.6 ml/min 
at a doses of 0.6–5.2 mg/m2, respectively. Following doses 
of 7.8, 11.7 and 17 mg/m2, clearance was 223.1, 221.5 
and 109.6 ml/min. Clearance was rapid (mean half-life 
7.1 ± 3.8 to 15.9 ± 3.6 min). there did not appear to be 
any correlation of dose with half-life. at doses of 5.2 mg/
m2 and above, plasma concentrations reached the predicted 
“therapeutic” concentrations that demonstrated activity in 
vitro in all pre-clinical studies. at the highest dose level 
tested, mean Cmax and aUC0–∞ were 4,760 ± 113 ng/ml 
and 325,709 ± 73,205 ng*min/ml, respectively.
Pharmacodynamics
Sustained decreases in lH and FSH in three breast cancer 
patients were indicative of eP-100’s pharmacological activ-
ity on pituitary gonadotropes. One patient treated at dose 
level of 7.8 mg/m2 had an 88 % reduction from baseline 
FSH (127–15 U/l) and lH reduction of 96 % (24–1 U/l). 
the second patient (11.7 mg/m2) had FSH decrease by 
81 % (21–4 U/l) and lH decrease from 1.2 U/l at baseline 
to less than 1 U/l. the third patient (26 mg/m2) had FSH 
decrease by 85 % (27–4 U/l) and lH decrease by 95 % 
(27–1.3 U/l).
antibodies to eP-100 were not detected at any dose 
level.
antitumor activity
Clinical benefit was observed in seven patients (19 %), all 
of whom had stable disease for 16 weeks or longer while 
receiving eP-100. Diagnoses of patients with stable disease 
included carcinoid (0.6 mg/m2), pancreatic cancer (0.9 mg/
m2), two ovarian cancers (2.6 and 11.7 mg/m2), two breast 
cancers (11.7 and 17.5 mg/m2) and one endometrial can-
cer (26 mg/m2), with at least 16 weeks’ SD. no objective 
tumor responses were seen by reCISt version 1.1, and 
there were no treatment-related decreases in relevant tumor 
biomarkers (Ca-125 or PSa) or CtC values.
Discussion
eP-100 is a unique, targeted anticancer fusion peptide, 
designed to be selectively toxic to cancer cells expressing 
lHrH receptor. the primary objectives of this study were 
to determine the MtD and Dlt of eP-100 and to establish 
a dose regimen of eP-100 recommended for future phase 2 
protocols. MtD was not reached at the highest dose level 
tested. the recommended dose for phase 2 protocols is 
Fig. 2  a Mean plasma con-
centration versus time curve by 
dose level for patients treated 
with a 30-min infusion of eP-
100. b Mean plasma concentra-
tion versus time curve by dose 
level for patients treated with a 
60-min infusion of eP-100
Cohort 1-7













































































* Infusion time increased from 30 to 60 minutes
Fig. 3  Plasma exposure [plasma concentration (Cmax) vs dose level] 
among 37 patients treated with eP-100 in a first-in-human phase I 
trial
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40 mg/m2 by IV infusion over 1 h twice weekly for 3 of 
4 weeks per cycle at a dose concentration of 0.5 mg/ml. 
to maximize the chance of therapeutic efficacy, the highest 
dose level tested was recommended for phase 2 trials.
results of the study show that eP-100 administered as 
an IV infusion twice weekly for 3 out of 4 weeks per cycle 
was well tolerated and displayed reproducible PK and PD 
profiles. toxicity was minimal. eP-100 was well toler-
ated after IV infusion in human subjects with advanced 
solid tumors. One patient experienced a grade 2 alt/aSt 
increase at 11.7 mg/m2, which reversed after withholding 
eP-100 for 2 weeks. this finding did not meet criteria for 
a Dlt, and no other Dlt were observed among three other 
patients treated at this or subsequent dose levels. the most 
frequent ae were IrDrs. ae other than IrDrs were few 
in number and were classified as unrelated or unlikely to be 
related to eP-100. all ae, with the exception of IrDrs, are 
expected and routine for patients with advanced cancers.
the mechanism for eP-100-associated IrDrs is not 
known. Pre-clinical studies in mice and beagle dogs sug-
gest eP-100 may trigger histamine release based on clinical 
signs of swelling, redness or raised areas on the face and 
ears, neck, trunk and/or limbs of affected animals. Clini-
cal signs of histamine release were eliminated in a female 
dog and lessened in a male dog when diphenhydramine 
was administered. therefore, histamine release may cause 
IrDrs, but it remains unclear how eP-100 triggers IrDrs 
in humans and why the reaction is seen in skin only. among 
patients experiencing IrDrs, hematology and chemistry 
profiles were unchanged, eosinophilia did not occur and 
no indicators of inflammatory response were detectable in 
serum. IrDrs were apparently concentration dependent. 
no IrDrs were reported in the four lowest dose cohorts 
(0.6–1.7 mg/m2, dose concentration 0.01–0.03 mg/ml). 
IrDrs incidence was lower when eP-100 infusion times 
were increased from 30 to 60 min. IrDrs incidence then 
increased again in the higher dose cohorts above a dose 
concentration of 0.26 mg/ml, at 17.5 mg/m2. although we 
observed more IrDrs with increasing dose concentration, 
IrDrs are less likely dependent on the total administered 
dose of eP-100. IrDrs were reduced by reducing the infu-
sion rate, thus extending the infusion time, resulting in 
complete dose administration. Pre-treatment with antihis-
tamines, H2-antagonists and corticosteroids did not fully 
eliminate IrDrs, but seemed to lessen the severity. none 
of the patients experienced typical “cytokine-release-type 
infusion reactions,” suggesting that the cytokine release 
mechanism is unlikely.
this study also sought to determine the pharmacokinet-
ics of eP-100. During IV infusion, eP-100 concentrations 
rise rapidly and decrease in an exponential fashion on its 
completion. eP-100 displays nonlinear pharmacokinetics. 
the terminal half-life of eP-100 is short, at approximately 
15 min at the highest dose tested. there did not appear to be 
any correlation of dose with half-life. Clearance appeared 
relatively consistent across dose levels. Inter-subject vari-
ability was moderate at each dose level with the %CV of 
Cmax and aUC0–∞ values ranging from 2 (at 40 mg/m2) to 
71.9 (at 5.2 mg/m2) and 7.5 (at 1.7 mg/m2) to 65 (at 26 mg/
m2), respectively. the decrease in clearance in the majority 
of subjects with an increase in dose may be suggestive of 
saturation of a clearance mechanism for eP-100. the Vz is 
consistent with the plasma volume, 40–60 ml/kg, suggest-
ing little extravascular distribution at the higher doses.
evidence of eP-100’s biological activity is confirmed by 
sustained decreases in lH and FSH only in three patients 
(8 %) treated at dose levels 7.6, 11.7 and 26 mg/m2. each of 
these subjects had breast cancer. this finding suggests the 
lHrH agonist portion of eP-100 retains the ability to bind 
and suppress gonadotropin release from the anterior pitui-
tary in some patients. Other pituitary hormones (aCtH and 
tSH) were not affected, indicating that the reduction in the 
levels of FSH and lH in plasma of the three patients was 
mediated via lHrH receptors on gonadotropes. a lack of 
aDa provides reassurance that prolonged administration 
of eP-100 does not result in autoimmunity to endogenous 
lHrH.
eP-100 as a single agent did not produce objective tumor 
responses. Stable disease for more than 3 months was 
observed in seven patients (two breast cancers, two ovarian 
and one each of carcinoid, pancreatic and endometrial can-
cer). Disease stability recorded in these few patients may 
have resulted from eP-100, but it could be due to underly-
ing tumor biology. We cannot make a definite conclusion 
from the available data; further validation of eP-100 clini-
cal activity requires additional clinical trials.
eP-100 was safe even with increasing drug exposure 
that was achieved by extending the infusion time. Increased 
infusion time increased circulating drug levels, which rap-
idly declined after infusion cessation. Further studies for 
increasing eP-100 exposure could help to optimize dosing 
and increase antitumor activity. Since eP-100 is comprised 
of l-amino acids, it is readily degraded by proteases in cir-
culation or released from lysed tumor cells. Improvement 
of the formulation, for example as a targeted liposome or 
nanoparticle, could enhance the stability and bioavailability 
of eP-100.
In vitro studies of eP-100 in combination with P-gly-
coprotein 1 (pgp)-substrates (doxorubicin, paclitaxel, 
vinorelbine, vincristine) and non-pgp substrates (cisplati-
num, 5-fluorouracil) showed reversion of drug resistance 
and potentiation of toxicity in lHrH-receptor-positive cell 
lines [39, 40]. Mechanistic studies suggest that the synergy 
between eP-100 and drugs such as paclitaxel and doxoru-
bicin were mediated via inhibition of pgp [39, 40]. In an 
in vivo breast cancer model, combination eP-100 with 
940 Cancer Chemother Pharmacol (2014) 73:931–941
1 3
paclitaxel was well tolerated [esperance, data on file]. a 
phase 2 clinical trial testing eP-100 with paclitaxel versus 
paclitaxel alone for patients with advanced ovarian cancer 
requiring second- or third-line treatment is ongoing [41].
Pre-clinical and now clinical studies demonstrate that 
eP-100 is a safe, well-tolerated drug that causes no seri-
ous organ toxicity and has reliable pharmacokinetic proper-
ties. Dermatologic reactions during eP-100 infusion appear 
manageable and require no additional premedication to pre-
vent reactions than is given routinely prior to infusions of 
anticancer agents such as paclitaxel. the PD data support 
the lHrH agonist activity of the drug. Based on pre-clini-
cal models, further clinical trials of eP-100 in combination 
with pgp substrates are warranted.
Open Access this article is distributed under the terms of the Crea-
tive Commons attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
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